2022
DOI: 10.1002/alr.22974
|View full text |Cite
|
Sign up to set email alerts
|

Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations

Abstract: Background: Cystic fibrosis (CF) is a multisystem disease that often requires otolaryngology care. Individuals with CF commonly have chronic rhinosinusitis but also present with hearing loss and dysphonia. Given these manifestations of CF, otolaryngologists are frequently involved in the care of patients with CF; however, there is limited consensus on optimal management of sinonasal, otologic, and laryngologic symptoms. Methods:The Cystic Fibrosis Foundation convened a multidisciplinary team of otolaryngologis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
23
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

5
3

Authors

Journals

citations
Cited by 32 publications
(25 citation statements)
references
References 134 publications
(251 reference statements)
1
23
0
1
Order By: Relevance
“…In the United States, the CF Foundation recently published guidelines for the management of CF CRS ( 14 ). Our study advances the growing body of literature establishing the sinuses as an important site of chronic infection along the respiratory tract of people with CF.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In the United States, the CF Foundation recently published guidelines for the management of CF CRS ( 14 ). Our study advances the growing body of literature establishing the sinuses as an important site of chronic infection along the respiratory tract of people with CF.…”
Section: Discussionmentioning
confidence: 99%
“…Together, these studies strongly suggest that CF CRS impacts LRT disease. Recently developed standard of care guidelines for the management of CF CRS also support this notion ( 14 ). One gap in the CF CRS literature is our lack of understanding regarding whether and how CF sinus communities change over time as the conditions in the surrounding host environment change (e.g., during periods of increased inflammation and/or exacerbation of symptoms).…”
Section: Introductionmentioning
confidence: 92%
“…In cases of recalcitrant maxillary sinus disease and particularly in cystic fibrosis patients, modified endoscopic medial maxillectomy (MEMM) with local mucosal nasal floor flap serves as an advanced technique to achieve disease control (Figure 2). 14,5156 The MEMM is more extensive than the EMMA but still preserves the anterior head of the inferior turbinate and nasolacrimal system. The opening is extended to the anterior maxillary wall underneath the inferior turbinate and nasolacrimal valve.…”
Section: Reviewmentioning
confidence: 99%
“…The American Academy of Audiology recommends baseline testing with high‐frequency audiometry within 2 days of initiation of aminoglycoside therapy and follow‐up testing after drug discontinuation, with no clear guidance on timing for inhaled versus IV therapy 2 . Recently published Cystic Fibrosis Foundation (CFF) Otolaryngology Care Multidisciplinary Consensus Recommendations recommend baseline audiological evaluation for PwCF, who may receive ototoxic therapies, with at least annual monitoring for patients receiving ototoxic medications and monitoring for each course of ototoxic medications for those with established hearing loss 3 …”
Section: Figurementioning
confidence: 99%
“…2 annual monitoring for patients receiving ototoxic medications and monitoring for each course of ototoxic medications for those with established hearing loss. 3 Unfortunately, the majority CF centers worldwide do not have a standard protocol for assessing ototoxicity. Of CF centers in the United Kingdom and Australia, only 13% and 15%, respectively, routinely assess for ototoxicity in their patients.…”
mentioning
confidence: 99%